HeLa
HeLa is a cell type in an immortal cell line used in scientific research. It is the oldest and most commonly used human cell line. The line was derived from cervical cancer cells taken on February 8, 1951, from Henrietta Lacks, a patient who died of cancer on October 4, 1951. The cell line was found to be remarkably durable and prolific, which warrants its extensive use in scientific research.
History[edit]
The cells from Henrietta Lacks were taken without her knowledge or consent, which was common practice at the time. Her family was not made aware of the line's existence until 1975. Since the cells' mass production and commercialization, Lacks's family have never received any financial compensation or recognition for their contribution.
Characteristics[edit]
HeLa cells are notable for their ability to reproduce indefinitely under specific conditions. This characteristic makes them a good model for studying the effects of various variables on cell growth and metabolism. They have been used in research to develop the polio vaccine, study cancer, and advance in vitro fertilization, cloning, and gene mapping.
Ethical Issues[edit]
The use of HeLa cells has raised ethical and legal issues, including informed consent and privacy. It has prompted changes in U.S. law and changes in practices regarding informed consent and compensation in genetic research.
In Popular Culture[edit]
The story of Henrietta Lacks and HeLa cells was popularized by Rebecca Skloot's 2010 book, The Immortal Life of Henrietta Lacks, and a subsequent HBO film of the same name starring Oprah Winfrey.
See Also[edit]
References[edit]
HeLa[edit]
-
HeLa-IV
-
HeLa-I
-
HeLa cells stained with antibody to actin (green), vimentin (red) and DNA (blue)
-
HeLa-Tubulin-HSP60-Fibrillarin-DNA
-
Henrietta Lacks statue, Bristol, RHS
-
HeLa-II
-
HeLa-III
-
HeLa-V
-
HeLa cells stained with Hoechst 33258
-
Ki67-Tubulin-2
-
Nuclear envelope of one cancerous HeLa cell
-
Plasma Membrane and Nuclear Envelope
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
